Sleep Apnea

Snoring, Sleep Apnea and Type 2 Diabetes: A Two-Way Street

Sleep apnea and type 2 diabetes travel together far more often than obesity alone explains, and each appears to worsen the other. What the evidence supports, and what treating one does to the other.

These two conditions overlap heavily, and the easy explanation — they share obesity as a cause — turns out to be incomplete.

The best current synthesis is a state-of-the-art review in Chest (Reutrakul and Mokhlesi, 2017), which is the source for most of what follows and worth reading directly if you have both conditions.

How much overlap

Very high in both directions. Studies of people with type 2 diabetes consistently find obstructive sleep apnea in a large majority when they are actually tested for it, and most of those cases are undiagnosed at the point of testing. The reverse direction shows a similar picture: rates of impaired glucose tolerance and diabetes among people with apnea run well above population baseline.

Obesity explains a large part of that, and honest reporting has to lead with it. Both conditions are driven hard by weight, and any association study that adjusts imperfectly for adiposity will overstate the independent link. But the association survives adjustment in most analyses, which is the reason the field treats it as more than coincidence.

Why apnea might worsen glucose control

Three mechanisms, all plausible and none individually proven in humans:

Intermittent hypoxia. Repeated cycles of oxygen desaturation and reoxygenation drive oxidative stress and inflammation, both of which impair insulin signalling. This is the mechanism with the most experimental support.

Sympathetic activation. Each obstructive event ends in an arousal with a catecholamine surge. Chronic sympathetic overactivity raises hepatic glucose output and reduces peripheral insulin sensitivity.

Sleep fragmentation. Independent of the breathing, badly fragmented sleep impairs glucose tolerance — this has been shown experimentally in healthy volunteers, where a few nights of disrupted deep sleep measurably worsen insulin sensitivity.

Why diabetes might worsen apnea

The less-discussed direction. Diabetic autonomic neuropathy can impair the reflex control of the upper airway dilator muscles and blunt the ventilatory response to hypoxia and hypercapnia. That is a mechanism for diabetes making breathing during sleep worse, independent of weight.

Which is why "two-way street" is the accurate description rather than a rhetorical flourish.

Does treating apnea improve blood sugar

This is where the evidence gets weaker, and where marketing tends to run ahead of it.

Randomised trials of CPAP with glycaemic endpoints have produced mixed and generally modest results. Some show improvement in insulin sensitivity or HbA1c, some show none. The trials are complicated by short duration, by adherence that is often poor in the treatment arm, and by the fact that CPAP does not cause weight loss — and may be associated with slight weight gain in some studies.

The fair reading: treat apnea because it is worth treating on its own merits, and do not expect it to substitute for diabetes management. Anyone claiming CPAP will fix your HbA1c is overselling.

Where the levers actually overlap

Weight. The dominant shared lever, and the only intervention with strong evidence in both conditions simultaneously. Modest sustained weight loss improves apnea severity and glycaemic control at the same time. Weight and snoring.

GLP-1 and dual agonist drugs. Two 52-week randomised trials of tirzepatide in adults with moderate-to-severe apnea and obesity showed large reductions in apnea severity (NEJM 2024). For someone with both conditions this is the most interesting development in years — one drug class with trial evidence in each. It is not a snoring treatment for people without those indications. What the trials showed.

Alcohol. Worsens nocturnal breathing and carries its own glycaemic effects. Alcohol and snoring.

The practical point

If you have type 2 diabetes and you snore, ask to be screened for sleep apnea. The prevalence is high enough, the screening cheap enough, and the diagnosis useful enough that it is a reasonable ask even without daytime symptoms — and daytime sleepiness is frequently absent or attributed to the diabetes.

If you have sleep apnea and have not had your glucose checked recently, get it checked. Same logic in reverse.

Screening questions · Home sleep testing · What to tell the doctor.

What does not help

No over-the-counter snoring product affects blood sugar, and none of them treats obstructive sleep apnea. Nasal strips, mouth tape and anti-snoring pillows change airflow and noise. That is the whole of their claim, and in the context of diabetes it is beside the point.

The risk specific to this group is delay: quietening snoring with a product, feeling that the problem is addressed, and not getting tested. Snoring versus apnea.

Common questions

Does sleep apnea cause diabetes?
The association survives adjustment for obesity in most analyses, and there are plausible mechanisms through intermittent hypoxia, sympathetic activation and sleep fragmentation. Causation is not established, and shared obesity explains a large share of the overlap.
How common is sleep apnea in people with type 2 diabetes?
Studies that actually test people with type 2 diabetes find obstructive sleep apnea in a large majority, and most cases are undiagnosed at the point of testing. That is why screening is reasonable even without daytime sleepiness.
Will CPAP lower my HbA1c?
Randomised trials with glycaemic endpoints have been mixed and generally modest. Treat apnea on its own merits and continue diabetes management as normal — CPAP is not a substitute for it.
Can diabetes make sleep apnea worse?
Plausibly. Diabetic autonomic neuropathy can impair reflex control of the upper airway muscles and blunt the ventilatory response to low oxygen, which is a route to worse breathing during sleep independent of weight.
Do weight loss drugs help both?
Tirzepatide reduced apnea severity substantially in two 52-week randomised trials in adults with obesity and moderate-to-severe apnea, and drugs in this class are already used in type 2 diabetes. That combination makes them unusually relevant to people with both conditions.